Promising COVID-19 therapeutic drug to start phase 3 clinical trial in the United States
Recruitment of first U.S.-based patients in dapsone trial has started
Research on dysanapsis recognized by McGill Medstar Award for Trainees
Congratulations to RI-MUHC trainee Motahareh Vameghestahbanati!
Can inhaled corticosteroids alleviate early symptoms of COVID-19?
Results from the CONTAIN study conducted at the RI-MUHC reveal that ciclesonide is no better than placebo
Regular screening for tuberculosis in Inuit communities is cost-effective
A new study from RI-MUHC researchers published in CMAJ recommends regular screening to help reduce outbreaks
Ben Geboe awarded the 2021-2022 Dr. Margaret Becklake Fellowship for his research with urban Indigenous populations
The RI-MUHC postdoc is working on a culturally safe framework for TB...
RI-MUHC team detects impact of HIV antiretroviral therapy on the anti-tuberculosis immune response
Alveolar macrophages, cells important for protection from tuberculosis infection, are adversely impacted by...
The 2021 RI-MUHC Annual Report is online!
An invitation from Dr. Rhian Touyz
Two members of the RI-MUHC elected fellows of the Canadian Academy of Health Sciences
Congratulations to Jean Bourbeau and Togas Tulandi!
RI-MUHC researchers contribute to global study of babies born with birth defects
A new study published in The Lancet finds that survival for babies born with a birth defect – otherwise known...
RI-MUHC success in grant competition for transplantation research
Researchers awarded funds from the Canadian Donation and Transplantation Research Program for...